APA

André T., Iveson T., Labianca R., Meyerhardt J. A., Souglakos I., Yoshino T., Paul J., Sobrero A., Taieb J., Shields A. F., Ohtsu A., Grothey A. & Sargent D. J. (2013). The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. : Current colorectal cancer reports.

Chicago

André Thierry, Iveson Timothy, Labianca Roberto, Meyerhardt Jeffrey A, Souglakos Ioannis, Yoshino Takayuki, Paul James, Sobrero Alberto, Taieb Julien, Shields Anthony F, Ohtsu Atsushi, Grothey Axel and Sargent Daniel J. 2013. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. : Current colorectal cancer reports.

Harvard

André T., Iveson T., Labianca R., Meyerhardt J. A., Souglakos I., Yoshino T., Paul J., Sobrero A., Taieb J., Shields A. F., Ohtsu A., Grothey A. and Sargent D. J. (2013). The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. : Current colorectal cancer reports.

MLA

André Thierry, Iveson Timothy, Labianca Roberto, Meyerhardt Jeffrey A, Souglakos Ioannis, Yoshino Takayuki, Paul James, Sobrero Alberto, Taieb Julien, Shields Anthony F, Ohtsu Atsushi, Grothey Axel and Sargent Daniel J. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. : Current colorectal cancer reports. 2013.